MRK: Keytruda Sales Surge—Unlocking New Growth Potential!

Merck & Co. (NYSE: MRK) is riding a wave of growth driven by its blockbuster cancer immunotherapy Keytruda. In the latest quarter, sales of Keytruda – Merck’s top-selling drug – jumped 19% year-on-year to $7.84 billion (www.clickondetroit.com). This powerhouse treatment contributed a record $25.0 billion in 2023 revenue (content.edgar-online.com) and continued to accelerate into 2024, approaching the $30 billion mark for the year. Keytruda’s success has propelled Merck’s overall sales higher and solidified its position as a premier oncology player. However, with Keytruda now comprising a large share of Merck’s ~$60 billion annual revenue, the company faces a balancing act: leveraging today’s Keytruda-fueled momentum while preparing for tomorrow’s challenges (notably, eventual patent expiry). Below, we examine Merck’s dividend profile, leverage and coverage, valuation, and the risks and open questions that investors should weigh.

Dividend Policy, History & Yield

Merck is a long-established dividend payer with a 15-year streak of consecutive annual dividend increases. Most recently, the Board lifted the quarterly dividend to $0.85 per share (annualized $3.40) for early 2026 (www.streetinsider.com), up from $0.81 in 2025 (msd2024ir.q4web.com) and $0.77 in 2024 (content.edgar-online.com). At the current share price, this equates to a dividend yield of roughly 2.8% (www.streetinsider.com), on par with big-pharma peers. Merck’s dividend growth has been steady – for instance, the 2024 increase was ~5.5% (from $0.73 to $0.77 quarterly) and the 2025 increase ~5.2% to $0.81. The payout ratio remains moderate. In 2023, Merck paid out $7.45 billion in dividends (content.edgar-online.com), which was about 44% of non-GAAP earnings and roughly 80% of that year’s free cash flow. This suggests the dividend is well covered by underlying profits, though cash flow was temporarily pressured by tax law changes (more on that below). Management’s signaling is shareholder-friendly – alongside dividends, Merck executes share buybacks (e.g. $1.3 billion repurchased in 2023) (content.edgar-online.com) – but the dividend remains the primary vehicle for returning capital. Overall, Merck offers a solid yield backed by a stable, growing payout, although its ~50% payout ratio means future dividend growth will likely track earnings growth.

Leverage & Debt Maturities

Merck maintains a conservative balance sheet, using debt strategically to finance growth. As of year-end 2023, long-term debt was about $33.7 billion (up from $28.7 billion in 2022) (content.edgar-online.com), plus ~$1.4 billion in current borrowings – bringing total debt to ~$35 billion. This increase reflects Merck’s debt-funded acquisitions during the year, notably the $5.9 billion debt issuance in May 2023 used to help acquire Prometheus Biosciences (content.edgar-online.com). Even after these deals, Merck’s leverage is reasonable: year-end cash was $6.84 billion (content.edgar-online.com), so net debt stood near $28 billion, and total debt was about one-third of total capitalization (content.edgar-online.com). Importantly, Merck has no liquidity crunch in sight – it generates strong cash flows and has $6.0 billion in undrawn credit facilities (maturing 2028) for backup liquidity (content.edgar-online.com). Recent debt maturities have been handled smoothly: for example, Merck repaid a $1.75 billion note that came due in 2023 from available funds (content.edgar-online.com). The debt maturity schedule is well staggered with no outsized near-term maturities disclosed (beyond normal commercial paper usage). Credit agencies rate Merck’s debt in the A range, reflecting its robust cash generation and prudent financial policy. In short, Merck’s leverage is manageable, and the company has ample financial flexibility to support R&D, acquisitions, and shareholder payouts even as it carries moderate debt from recent growth initiatives.

Cash Flow & Coverage

Cash flows comfortably cover Merck’s obligations. In 2023, cash from operations was $13.0 billion (content.edgar-online.com) despite a headwind from U.S. tax law (which now requires capitalization of R&D costs, temporarily boosting cash taxes). Even with that drag, operating cash flow was nearly 11× the annual interest expense of $1.15 billion (content.edgar-online.com) – a very strong interest coverage ratio. By another measure, 2023 free cash flow (after $3.9 billion of capital expenditures (content.edgar-online.com) (content.edgar-online.com)) was about $9.1 billion, providing 1.2× coverage of that year’s $7.4 billion dividend outlay (content.edgar-online.com). This coverage was tighter than in 2022 (when cash flow was higher at $19 billion (content.edgar-online.com)), but the decline is largely due to timing of tax payments rather than a business downturn. Merck expects operating cash flow to strengthen over the next few years, aided by growth in earnings and a potential easing of the R&D tax rule (an item to watch in Washington). From a liquidity standpoint, Merck’s cash generation plus $7+ billion in cash-on-hand provide a solid buffer for debt servicing and dividends. The company’s cash flow-to-debt ratio of ~0.4:1 in 2023 (content.edgar-online.com), while lower than the prior year’s 0.6:1, should improve as one-time tax impacts abate. Overall, Merck’s coverage ratios indicate a healthy financial cushion – it can comfortably meet interest, debt repayments, and dividend commitments with room to spare.

Valuation & Comps

Merck’s valuation appears reasonable relative to its pharma peers, balancing robust near-term growth with longer-term uncertainties. The stock currently trades around 18× forward earnings (www.koyfin.com), which is roughly in line with the broader market and a premium to certain pharma peers facing stagnation. At ~18×, Merck is valued higher than companies like Pfizer or Bristol Myers (who trade at low-teens or single-digit multiples amid their own patent cliffs), but it trades at a discount to high-growth biotech-oriented peers (for example, Eli Lilly’s forward P/E is far higher thanks to its obesity/diabetes franchise). Merck’s dividend yield ~2.8% (www.streetinsider.com) is comparable to Johnson & Johnson and slightly below Pfizer or AbbVie, reflecting the market’s view of Merck as a stable but growing income play. Another lens: Merck’s enterprise value is about 13× its EBITDA, a middling level in the industry. This moderate valuation suggests that investors are already pricing in Merck’s strong current product momentum and the future headwind of Keytruda’s patent expiry. In other words, Merck is not a deep value stock, nor is it priced for perfection. The upside in share price will likely hinge on how well the company can sustain growth beyond Keytruda. Given Merck’s solid pipeline investments and the time still left on Keytruda’s exclusivity, many analysts view the stock as fairly valued to slightly undervalued on a risk-adjusted basis. For now, Merck offers a blend of ~mid-single-digit revenue growth (driven by Keytruda and vaccines) and a near-3% yield – a combination that supports its current valuation multiples.

Risks & Red Flags

Despite Merck’s recent successes, investors should be mindful of several key risks. Patent expiration of Keytruda is the elephant in the room. Primary U.S. patents for Keytruda begin to expire in 2028 (content.edgar-online.com), which could open the door to biosimilar competition and a sharp revenue decline for this ~$30 billion franchise. The company is highly reliant on Keytruda – the drug accounts for roughly 40–45% of Merck’s pharmaceutical sales – so any disruption, whether patent-related or a competing therapy, poses a significant risk. Merck’s strategy to counter this is aggressive investment in R&D and acquisitions, but these initiatives carry execution risk. The pipeline and M&A bets must pay off to fill the impending revenue gap. For instance, Merck spent $10.8 billion to acquire Prometheus Biosciences in 2023 (www.axios.com) (gaining a promising immunology drug candidate) and agreed to buy Verona Pharma for ~$10 billion in 2025 (adding an inhaled COPD medication) (abcnews.go.com). It also struck a deal to acquire Cidara Therapeutics for ~$9 billion to expand its antiviral portfolio ahead of Keytruda’s LOE (cincodias.elpais.com). These are bold moves – but if the acquired drug candidates falter in trials or face delays, Merck could be left with heavy debt and little to show when Keytruda’s exclusivity lapses.

Another risk is competition in oncology. While Keytruda essentially defines the PD-1 immunotherapy market today, rivals like Bristol Myers’ Opdivo and newer entrants (including potential next-generation immunotherapies, bispecific antibodies, and cell therapies) are vying for share. Any clinical advances by competitors could erode Keytruda’s growth or limit its future indications. Moreover, pricing pressure is a constant overhang – global healthcare systems and the U.S. Inflation Reduction Act are pushing for drug price negotiations, which may eventually include a product as widely used as Keytruda (though likely only once it’s post-exclusivity). Outside oncology, Merck faces generic erosion on older drugs (e.g. diabetes drugs Januvia/Janumet are already seeing declines (content.edgar-online.com)) and occasional manufacturing or regulatory setbacks (the recent Gardasil vaccine shipment pause in China is a reminder of operational risks (www.clickondetroit.com)).

In terms of financial red flags, Merck’s GAAP earnings volatility bears mention. The company’s heavy use of acquisitions and collaborations leads to large intangible amortization and one-time charges – for example, Merck barely broke even on a GAAP basis in 2023 (GAAP EPS was only $0.14) due to acquisition-related costs (www.biospace.com). While these are mostly non-cash and adjusted in “non-GAAP” results, they highlight accounting noise and the cost of buying growth. Lastly, Merck’s cash flows have been dented by the new R&D tax capitalization rules (contributing to a ~$6 billion drop in operating cash in 2023 (content.edgar-online.com)). This is more a timing issue than a true economic loss, but it does mean near-term free cash flow is tighter, and if such laws persist, Merck might lean more on debt for big investments. None of these issues are crippling given Merck’s strong core business, but they warrant monitoring. In summary, Merck’s greatest risk is the looming Keytruda cliff, and while management is taking prudent steps to mitigate it, the execution risk of those steps (pipeline success, smart capital allocation) is substantial.

Open Questions & Outlook

How will Merck bridge the post-Keytruda gap? This is the central question for Merck’s future. Keytruda’s U.S. patent expiration in 2028 could remove tens of billions of high-margin revenue within a few years thereafter. Merck is clearly planning ahead – the company explicitly positioned its recent acquisitions (like Verona and Cidara) as strategic moves to “anticipate the loss of Keytruda’s patent” (cincodias.elpais.com). It’s also investing heavily in its internal pipeline, from oncology combinations to vaccines. One promising avenue is Merck’s partnership with Moderna on a personalized cancer vaccine: an mRNA vaccine (V940) combined with Keytruda that showed positive Phase 2 results in melanoma (content.edgar-online.com). If this and other pipeline candidates (e.g. Merck’s own next-gen immunotherapy MK-1308A (content.edgar-online.com)) succeed, they could partially offset Keytruda’s eventual decline or extend its franchise in new ways. However, these are still in clinical trials – will they arrive in time and be big enough? Investors will be watching upcoming trial readouts and FDA decisions closely.

Another open question is Merck’s future business mix. The company has already slimmed down by spinning off Organon in 2021, and it retains a sizable Animal Health division that contributes stable revenue (~$6 billion annually). Will Merck consider separating or monetizing Animal Health to unlock value, or does it prefer the diversification it provides? Thus far, management has kept Animal Health, but pressure could grow if core pharma growth slows. Additionally, Merck’s appetite for mega-acquisitions remains a topic of speculation. With ~$30 billion in annual free cash flow projected by the late 2020s (before Keytruda’s drop-off) and a strong balance sheet, Merck has capacity for deals. Could Merck pursue a transformative acquisition (as some rivals have) to rewrite its growth story – or will it stick to bolt-on deals? The decision may hinge on how confident management is in its current pipeline.

Finally, on the financial front, will Merck’s cash flows rebound to prior levels? The resolution of the R&D tax capitalization issue (if Congress acts) could significantly boost annual cash flow, improving dividend coverage and debt paydown capacity. This is an external factor to watch in the next year or two. Additionally, as Keytruda’s growth eventually plateaus, Merck’s top-line will need new engines. Gardasil (the HPV vaccine) is one notable driver – its sales hit $8.9 billion in 2023 (content.edgar-online.com) and demand (especially in emerging markets) remains robust – but a recent hiccup in China (shipment pause) raises the question of how quickly that growth can resume.

In conclusion, Merck is in a phase of reaping the rewards of past innovation (Keytruda, Gardasil) while vigorously sowing seeds for the future. The next few years look bright: Keytruda is still surging in new indications and geographies, and Merck’s near-term guidance (2025 sales ~$64–65 billion (www.clickondetroit.com)) indicates continued growth. The dividend is secure and growing, and financial leverage is under control. The real test comes as the decade closes – Merck will need its pipeline and acquisitions to unlock new growth potential to replace its aging superstar. How effectively the company can execute that handoff remains the key open question for investors. In the meantime, Merck offers an attractive mix of current income and growth with the understanding that successful innovation (and perhaps further strategic deals) will determine whether today’s Keytruda-fueled performance can translate into sustainable long-term returns.

Sources: Key company data and statements were obtained from Merck’s 10-K filings and earnings releases, as well as authoritative financial media and news services (Associated Press, Business Wire, Axios). All inline citations reference these materials for verification.

For informational purposes only; not investment advice.